BioWorld MedTech

Sep. 22, 2016

Analysts sift through Abbott unit sale to find read-through for contested Alere deal

Abbott Laboratories' divestiture of its optics business could indicate that the company is ready to bite the figurative Alere Inc. bullet and move forward with that $5.8 billion acquisition – but not necessarily. Read More

Califf says combo products 'on my mind,' along with cross-center coordination

Spirox's Latera absorbable nasal implant technology demonstrates significant quality of life improvement

Weak clinical trial data in China leads to a rush of device withdrawals

Financings

Appointments and advancements

Product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.